Michael Curley

Michael Curley is a seasoned professional in the biotechnology and oncology fields, currently serving as Senior Director and Global Program Lead for Cell Therapy at Takeda Oncology since January 2017. With a robust background in cell therapy innovation, Curley has overseen the development and execution strategies for gamma delta cell therapy and allogeneic cord blood NK cell therapy. Prior roles at Takeda include leadership positions in I-O Biology and significant contributions to early Discovery programs. Curley's previous experience includes a Senior Scientist role at Merrimack Pharmaceuticals, where strategic priorities for MM-141 research were established. Additionally, research efforts at Massachusetts General Hospital and Joslin Diabetes Center focused on optimizing cancer models and characterizing tumor-initiating cells. Michael Curley holds a PhD in Biochemistry and a B.S. in Biotechnology from the University of Galway.